Introduction: Bone marrow derived mesenchymal stem cells (MSC) represent an attractive cellular
therapeutic target given their immunosuppressive and tolerogenic properties and relative
immune privilege. Preclinical studies and human trials in graft versus host disease
suggest potential efficacy in bronchiolitis obliterans syndrome (BOS). The purpose
of this dual centre, phase 1 study (www.clinicaltrials.gov NCT01175655) was to explore the feasibility and safety of delivery of allogeneic
MSC in patients with BOS complicating lung transplantation.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to CytotherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
